Architect & Engineering (A&E) Design Services at the National Center for Toxicological Research

The Food and Drug Administration, Office of Operations has a requirement for Architect & Engineering (A&E) Design Services.  The services will consist of engineering professional disciplines including architectural, interior design, landscape architectural, environmental, structural, civil, mechanical and electrical for the performance of planning, programming, surveys, studies, investigations, review of shop drawings, testing/collecting samples and equipment, and the preparation and development of reports, working drawings, specifications, cost estimates, other related documents and construction administrative services as required by the Food and Drug Administration at the Jefferson Lab Complex in Jefferson, AR. This contract is being procured in accordance with FAR 36.6 and selection will be non-project specific. Firms will be selected for negotiation, if necessary, based on demonstrated competence and qualifications for the required work.

The associated North American Industry Classification System (NAICS) Code is- 541310- Architectural Services; Small Business Size Standard is $8 Million.

This acquisition is a total small business set aside.

We anticipate a single award Indefinite Delivery/Indefinite Quantity contract.

The anticipated performance period of this contract will have a 5-year ordering period. The estimated not to exceed amount of $7,500,000 which can be increased via bi-lateral mod in the resultant contract. The one-time guaranteed minimum order amount for the entire five-year period is $10,000.00. Multiple task orders may be awarded with similar completion schedules and overlapping delivery dates.

Vendors are encouraged to sign up on the Interested Vendors List to receive

automated notification from beta.sam when changes are made to the posting; however, contractors are responsible to monitor this website for further information concerning this procurement.

Interested Parties with comments, questions, etc., shall respond to Warren Dutter at

warren.dutter@fda.hhs.gov prior to 1:00 PM Central Time on June 30, 2020.